NASDAQ Framework: PROCEPT BioRobotics Corporation

Surgical robotics company specializing in urology 1.

PROCEPT BioRobotics Corporation, headquartered in San Jose, California, is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System, an image-guided, surgical robotic system designed for minimally invasive urologic surgery, particularly targeting benign prostatic hyperplasia (BPH) 2 3 4. The AquaBeam Robotic System utilizes a single-use disposable handpiece to deliver Aquablation therapy, a procedure that has recently received a new CPT® Category I code from the American Medical Association 5. With significant institutional ownership and a strong market position, PROCEPT BioRobotics continues to innovate in the field of urology 6 7 8.

2: PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. View Source3: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. View Source4: PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver... View Source5: PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy View Source6: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source7: With 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional owners View Source8: A look at the shareholders of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 84% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). View Source

UNKNOWN

The provided facts do not specify whether PROCEPT BioRobotics Corporation is still led by its founders or if the founders are heavily involved.

MEDIUM RISK

PROCEPT BioRobotics Corporation exhibits a mixed financial outlook. On one hand, the company has demonstrated solid revenue growth, achieving an 82.51% increase as of March 31, 2024, which is higher than the average among its peers in the healthcare sector 9. Additionally, the company's debt-to-equity ratio is relatively low at 0.31, indicating a healthier balance between debt and equity 10. However, the company faces challenges in maximizing returns, as evidenced by its negative Return on Equity (ROE) of -9.53% and Return on Assets (ROA) of -6.59% 11 12. These factors suggest that while the company is growing, it still faces hurdles in achieving optimal financial performance, placing it in the medium risk category.

9: Revenue Growth: PROCEPT BioRobotics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 82.51%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. View Source10: Debt Management: PROCEPT BioRobotics's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. View Source11: Return on Equity (ROE): PROCEPT BioRobotics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.53%, the company may face hurdles in achieving optimal financial performance. View Source12: Return on Assets (ROA): PROCEPT BioRobotics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.59%, the company may face hurdles in achieving optimal financial performance. View Source

NO

The provided facts do not indicate that PROCEPT BioRobotics Corporation is launching any new product offerings. The focus is on their existing AquaBeam Robotic System and the recent CPT® Category I code for Aquablation therapy 13 14 15 16 17.

13: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source14: PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024 Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 View Source15: Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference View Source16: PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. View Source17: PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy View Source

PROCEPT BioRobotics Corporation's product roadmap and expansion strategy for 2024 through to 2026 focuses on leveraging its existing AquaBeam Robotic System and Aquablation therapy to solidify its market position in the urology sector. The company aims to capitalize on the recent establishment of a new CPT® Category I code for Aquablation therapy by the American Medical Association, which enhances the procedure's reimbursement prospects 18 19 20. Additionally, PROCEPT BioRobotics plans to continue presenting at key industry conferences, such as the Truist Securities MedTech Conference and the Leerink Partners Healthcare Crossroads Conference, to increase visibility and attract further institutional investment 21 22. The company is also expected to report financial results and host conference calls to keep investors informed, thereby maintaining transparency and fostering investor confidence 23 24.

18: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source19: PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy View Source20: Josh Jennings has given his Buy rating due to a combination of factors that indicate a favorable financial outlook for PROCEPT BioRobotics. One significant aspect is the company’s recent series of successes in securing reimbursements for its Aquablation therapy, which is used to treat benign prostatic hyperplasia. The Centers for Medicare & Medicaid Services (CMS) have not only provided full Medicare coverage for the therapy but have also proposed an increase in the reimbursement rate for procedures performed in both hospital outpatient departments and ambulatory surgical centers. This progression is seen as a direct result of the therapy’s strong safety and efficacy data influencing positive coverage decisions from CMS and private insurance providers. View Source21: Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference View Source22: PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference View Source23: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source24: PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024 View Source

Sources

1: PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. View Source2: PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. View Source3: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces. View Source4: PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver... View Source5: PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy View Source6: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source7: With 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional owners View Source8: A look at the shareholders of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 84% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). View Source9: Revenue Growth: PROCEPT BioRobotics displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 82.51%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. View Source10: Debt Management: PROCEPT BioRobotics's debt-to-equity ratio is below the industry average. With a ratio of 0.31, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors. View Source11: Return on Equity (ROE): PROCEPT BioRobotics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -9.53%, the company may face hurdles in achieving optimal financial performance. View Source12: Return on Assets (ROA): PROCEPT BioRobotics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.59%, the company may face hurdles in achieving optimal financial performance. View Source13: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source14: PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024 Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 View Source15: Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference View Source16: PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California. View Source17: PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy View Source18: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source19: PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy View Source20: Josh Jennings has given his Buy rating due to a combination of factors that indicate a favorable financial outlook for PROCEPT BioRobotics. One significant aspect is the company’s recent series of successes in securing reimbursements for its Aquablation therapy, which is used to treat benign prostatic hyperplasia. The Centers for Medicare & Medicaid Services (CMS) have not only provided full Medicare coverage for the therapy but have also proposed an increase in the reimbursement rate for procedures performed in both hospital outpatient departments and ambulatory surgical centers. This progression is seen as a direct result of the therapy’s strong safety and efficacy data influencing positive coverage decisions from CMS and private insurance providers. View Source21: Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024 PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference View Source22: PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference View Source23: Simply Wall St.•7 hours agoWith 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional ownersKey Insights Institutions' substantial holdings in PROCEPT BioRobotics implies that they have significant influence...GlobeNewswire•9 days agoPROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to tGuruFocus.com•last monthInsider Selling: EVP, CLO, Corporate Secretary Alaleh Nouri Sells Shares of PROCEPT BioRobotics ...Alaleh Nouri, the Executive Vice President, Chief Legal Officer, and Corporate Secretary of PROCEPT BioRobotics Corp (NASDAQ:PRCT), executed a sale of 10,000 shares of the company on June 17, 2024. Over the past year, Alaleh Nouri has sold a total of 108,621 shares of PROCEPT BioRobotics Corp and has not purchased any shares. The company's insider transaction history reveals a pattern of 25 insider sells and no insider buys over the same period.GlobeNewswire•last monthPROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapySAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association (“AMA”) has established a new Current Procedural Terminology (“CPT”) Category I code for transurethral waterjet resection of prostate tissue (“Aquablation therapy”) to treat benign prostatic hyperplasia (“BPH”). In rGlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recordiInvestor's Business Daily•2 months agoIntuitive Surgical, IBD Stock Of The Day, Feels Its Way Toward Buy PointIntuitive Surgical is IBD Stock Of The Day as the robotic surgery pioneer nears a buy point on hopes for its da Vinci 5 that lets surgeons feel each incision.GlobeNewswire•2 months agoPROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock ConferenceSAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at thGlobeNewswire•3 months agoReal-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizesSAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data shoSimply Wall St.•3 months agoPROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price TargetsPROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest quarterly results and things are looking...GuruFocus.com•3 months agoDirector Thomas Krummel Sells 20,000 Shares of PROCEPT BioRobotics Corp (PRCT)On May 1, 2024, Thomas Krummel, Director at PROCEPT BioRobotics Corp (NASDAQ:PRCT), sold 20,000 shares of the company. View Source24: PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024 View Source